Abstract
Breast cancer is the second most common cancer worldwide and the highest prevalence among women. Long follow-up is recommended after the diagnosis and treatment of breast cancer, and with age the risk of comorbidities increases. Current anticancer strategies have contributed to the increase in l of cancer survivors and in some cases the cancer becomes a "chronic disease". Studies indicate that patients with breast cancer survivors are at high risk for cardiovascular disease (CVD), osteoporosis and diabetes, admittedly a vulnerable population. Thus, with increasing life expectancy of women treated for breast cancer, similarly those without cancer, the risk of CVD death increases. CVD, especially coronary artery disease (CAD), shows that risk increases throughout life, with particular increase in women after menopause, when they occupy the major cause of mortality. Metabolic syndrome (MS) is known to associate itself with the increased risk of developing CVD and type II diabetes. It is defined as series of metabolic risk factors that include abdominal obesity, dyslipidemia, hypertension and dysglycemia. With the increasing effectiveness in the treatment of breast cancer, particularly with the use of antiestrogen therapy, there was an increase in the population of survivors of breast cancer. These patients have additional increased risk of metabolic syndrome resulting from excess body fat and effects of treatments. Evidence suggests that certain types of cancer treatment could increase the risk of developing MS in the survivors. Antiestrogen therapy for breast cancer may be associated with adverse effects on lipid profile and liver. Elevations in systemic inflammatory markers of CVD and the presence of MS have been associated with decreased survival in women with breast cancer. Objective: To evaluate the risk of metabolic syndrome in postmenopausal women treated for breast cancer followed at Botucatu Medical School, UNESP. Specific Objective: To evaluate the incidence and indicators of metabolic syndrome in postmenopausal women treated for breast cancer. Methods: This is clinical, analytical and comparative study. Will be included in the study group women with: (1) date of last menstrual period for at least 12 months and age ³ 45 years, (2) histological diagnosis of breast cancer, (3) have completed treatment with surgery, radiotherapy, chemotherapy and hormone therapy (when indicated), (4) be free of disease for at least five years, (5) non-alcoholic and non-addicted. The control group in a 1:3 ratio controls, will consist of women with last menstrual period for at least 12 months and age ³ 45 years without breast cancer, non-alcoholic or drug addict and matched by age and body mass index body. Will be collected through interviews, clinical data regarding cardiovascular risk and anthropometry, and data on breast cancer and blood lipids. Will be considered with metabolic syndrome in women who presented three or more diagnostic criteria proposed by the U.S. National Cholesterol Education Program (NCEP) Adult Treatment Panel III (NCEP-ATP III) (2001): waist circumference> 88 cm, triglycerides > 150 mg / dL, HDL cholesterol <50 mg / dL, blood pressure > 130/85 mmHg, fasting glucose > 100 mg / dL or under treatment. It is hoped that with the project of assessing the risk of metabolic syndrome in postmenopausal women treated for breast cancer may identify patients to cardiovascular risk thus proposing preventive measures effective in reducing the occurrence of manifest disease, the leading cause of mortality in this population, impacting significantly on the quality of life of patients.
|